Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SURGERY FOLLOWED BY INTRACAVITARY PLUS SYSTEMIC CHEMOTHERAPY IN MALIGNANT PLEURAL MESOTHELIOMA
Autore:
COLLEONI M; SARTORI F; CALABRO F; NELLI P; VICARIO G; SGARBOSSA G; GAION F; BORTOLOTTI L; TONIOLO L; MANENTE P;
Indirizzi:
ULSS 8,DIV MED ONCOL,VIA OSPED 1 I-30133 CASTELFRANCO VENE TV ITALY CITY HOSP,DIV MED ONCOL CASTELFRANCO VENE TV ITALY UNIV PADUA,DEPT THORAC SURG PADUA ITALY
Titolo Testata:
Tumori
fascicolo: 1, volume: 82, anno: 1996,
pagine: 53 - 56
SICI:
0300-8916(1996)82:1<53:SFBIPS>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
MULTIMODALITY THERAPY; CISPLATIN; DIFFUSE;
Keywords:
INTRACAVITARY CHEMOTHERAPY; MESOTHELIOMA; SURGERY; SYSTEMIC CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
M. Colleoni et al., "SURGERY FOLLOWED BY INTRACAVITARY PLUS SYSTEMIC CHEMOTHERAPY IN MALIGNANT PLEURAL MESOTHELIOMA", Tumori, 82(1), 1996, pp. 53-56

Abstract

Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m(2)) and cytarabine (1,000 mg/m(2)) for 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m(2)) and mitomycin-C (10 mg/m(2)) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects afterintracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:34:25